BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that its Quell Wearable Pain Relief Technology will be exhibited at the Pri-Med East Annual Conference in Boston on September 18-20, 2015 . The Pri-Med East Annual Conference curriculum is developed with the American College
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), announced today that the Quell Wearable Pain Relief Device is now available on Amazon. "Most of our consumers are already on Amazon and appreciate the platform's convenience and first class customer service.
BOSTON --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO) today announced that its Quell Wearable Pain Relief Technology will be featured at the PAINWeek 2015 National Conference this week in Las Vegas, Nevada . PAINWeek is the nation's largest pain conference for frontline clinicians with an
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), a health-care company that develops wearable medical technology and point-of-care tests, reported that Shai N. Gozani M.D ., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Rodman & Renshaw 17 th Annual Global
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases and sleep disorders, announced today that the Quell
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced preliminary results
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported that over 200,000
81% of subjects reported improvement in chronic pain and overall health Two-thirds of subjects reported decreased use of pain medications Clinically significant improvement in pain relief, sleep, general activity and walking ability WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc.
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. ( NURO ), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today reported progress in enlisting
WALTHAM, Mass. --(BUSINESS WIRE)-- NeuroMetrix, Inc. (NASDAQ:NURO), an innovative health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders, today announced an agreement
